

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

13 Jun 2026

### Evaluation of the Effect of Monthly Intravenous Pamidronate in the Treatment of Legg Calve Perthes in Children

#### Protocol summary

##### Study aim

Determining the effect of monthly pamidronate intravenous injection in addition to routine treatment in the treatment of children's LCP

##### Design

This research is a double-blind clinical trial with parallel groups using the random block method and sampling will be done by the available method among LCP patients in two intervention and control groups, and the sample size will be 30 people in each group. Was. The case group will receive pamidronate in addition to routine treatment. The Control group patients will receive routine treatment.

##### Settings and conduct

This study will be conducted on 60 patients with LCP referred to Mofid Hospital in 1402 and 1403. Patients will be randomly divided into two groups of 30 people. In the case group, pamidronate will be injected monthly and intravenously at 1 mg/kg/dose, and the control group will only receive routine treatment. Both groups will be the same in terms of the type of routine treatment received, the number of visits and other follow-up parameters. Before starting the study, imaging will be done for all patients to assess the condition of the femur bone. Also, this imaging will be repeated six months and one year later. Then, imaging findings, disease grade based on expert opinion and response to treatment will be compared between two groups.

##### Participants/Inclusion and exclusion criteria

The criteria for entering the study will be patients with LCPD and having consent to participate in the study. Exclusion criteria will be receiving previous treatment and receiving other similar drugs.

##### Intervention groups

Patients in the control group will receive routine treatment of the underlying disease. In addition to routine treatment, patients in the case group, will also receive pamidronate injections.

##### Main outcome variables

Disease grade, Response to treatment, Clinical signs, Imaging findings.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20230526058299N1**

Registration date: **2023-07-01, 1402/04/10**

Registration timing: **registered\_while\_recruiting**

Last update: **2023-07-01, 1402/04/10**

Update count: **0**

##### Registration date

2023-07-01, 1402/04/10

##### Registrant information

##### Name

Niloufar Shashaani

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2222 7021

##### Email address

shashaaniniloofar@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-06-22, 1402/04/01

##### Expected recruitment end date

2024-06-21, 1403/04/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the Effect of Monthly Intravenous Pamidronate in the Treatment of Legg Calve Perthes in Children

**Public title**

The effect of Pamidronate Injection in the Treatment of LCP Disease

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients with LCPD Consent to participate in the study

**Exclusion criteria:**

Received previous treatments receiving other similar drugs

**Age**

To 18 years old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Data analyser

**Sample size**

Target sample size: 60

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Among the 60 samples that meet the conditions for entering the study, people will be randomly divided into two groups, case and control, using the random block method. Using a calculator, random numbers from 1 to 60 will be generated, 30 numbers and the first number generated by the calculator will be assigned to the case group and the next 30 numbers will be assigned to the control group.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

In order to blind the statistical analyzer, a code will be assigned to the patients of each group.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee**

Name of ethics committee

Ethics Committee of Shahid Beheshti University of Medical Sciences

**Street address**

Shahid Beheshti University of Medical Sciences, Student Blvd., Valenjak, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1983969411

**Approval date**

2023-05-06, 1402/02/16

**Ethics committee reference number**

IR.SBMU.MSP.REC.1402.042

**Health conditions studied****1****Description of health condition studied**

Legg-Calve'-Perthes

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Disease Grade

**Timepoint**

Referral time, six months and one year after the intervention

**Method of measurement**

Imaging findings and physical examination

**2****Description**

Response to treatment

**Timepoint**

Referral time, six months and one year after the intervention

**Method of measurement**

Imaging findings and physical examination

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Intervention group: In addition to routine treatment, the group will receive pamidronate for 6 months. A 90 gram ampoule with a dose of 1 mg/kg will be injected every month. The drug will be prepared from Aburihan company and contains disodium pamidronate.

**Category**

Treatment - Drugs

**2**

**Description**

Control group: A group that will only receive routine treatment.

**Category**

Other

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Mofid Children's Hospital Rheumatology Clinic

**Full name of responsible person**

Reza Shiari

**Street address**

Mofid Children's Hospital, Shariati Ave, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1551415468

**Phone**

+98 21 2222 7021

**Email**

shiareza@yahoo.com

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Afshin Zarghi

**Street address**

Volenjek Ave., Shahid Beheshti University of Medical Sciences, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 23871

**Email**

info@sbmu.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Niloofar Shashaani

**Position**

Rheumatology resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Rhematology

**Street address**

Shariati Ave, Mofid Children's Hospital

**City**

Tehran

**Province**

Tehran

**Postal code**

1551415468

**Phone**

+98 21 2222 7021

**Email**

shashaaniniloofar@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Niloofar Shashaani

**Position**

Rheumatology Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Rheumatology

**Street address**

Shariati Ave, Mofid Children's Hospital

**City**

Tehran

**Province**

Tehran

**Postal code**

1551415468

**Phone**

+98 21 2222 7021

**Email**

## Person responsible for updating data

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Niloofer Shashaani

**Position**

Rheumatology Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Rhematology

**Street address**

Shariati Ave, Mofid Children's Hospital

**City**

Tehran

**Province**

Tehran

**Postal code**

1551415468

**Phone**

+98 21 2222 7021

**Email**

shashaaniloofar@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Demographic information and clinical trial results

**When the data will become available and for how long**

Access starts one year after results are published

**To whom data/document is available**

Researchers working in academic and scientific institutions

**Under which criteria data/document could be used**

Research on a related issue

**From where data/document is obtainable**

Niloofer Shashaani

**What processes are involved for a request to access data/document**

Communicating with the responsible person by email

**Comments**